A leader in the pharmacology of drugs used to treat cancer has been appointed to head UniSA’s School of Pharmacy and Medical Sciences
Professor Alan Boddy will join the School in July to spearhead the University’s pharmaceutical and cancer research in the new University of South Australia Cancer Research Institute.
The new UniSA Cancer Research Institute on North Terrace will house the University’s cancer, drug discovery and therapeutics research facilities. Second and third-year Pharmacy and Pharmaceutical Science students will also be based there in purpose-built, state-of-the-art teaching spaces.
Prof Boddy says he says he is excited to be joining UniSA as his interests and experience in pharmacology, and specifically the understanding of how the pharmacology of cancer drugs influences treatment outcomes, closely intertwine with UniSA’s innovative research and education principles.
“I have always believed that good teaching is supported by good research practices and that teaching and research work best in a collaborative approach,” Prof Boddy says.
“I have used my research experience in the development and coordination of novel teaching modules in pharmacology and oncology, at both undergraduate and postgraduate levels and my research interests and experience are closely aligned with those of the School and of the wider faculty.”
Prof Boddy brings a wealth of knowledge to UniSA. He has been Professor of Cancer Therapeutics and Personalised Medicine in the University of Sydney’s Faculty of Pharmacy since 2014. He holds a Bachelor of Science (Honours) Pharmacy and a PhD in Pharmacokinetics, both from The University of Manchester.
Pro Vice Chancellor of UniSA’s Division of Health Sciences Professor Robert Vink says he is delighted to welcome Prof Boddy to the leadership position.
“This is a really important time for the School of Pharmacy and Medical Sciences as it settles into purpose-built laboratories and teaching facilities in the UniSA Cancer Research Institute in Adelaide’s BioMed City and with increased focus on cancer research – Prof Boddy’s experience, knowledge and skills across research and teaching make him ideally suited to lead and build on the School’s strong track record,” Prof Vink says.
“Prof Boddy’s research focuses on the pharmacology of drugs used to treat cancer, spanning multiple aspects of cancer pharmacology, including drug analysis, pharmacogenetics, biomarkers and pharmacodynamics.
“He has attracted grant income, undertaken multiple collaborative projects, supervised students and published strongly in these areas over a number of years.
“Prof Boddy has also undertaken teaching in both Australia and the UK, with a strong focus on student engagement and the complementary relationship between teaching and research.”
Prof Boddy will take up his position on 23 July 2018.
Prof Vink also thanked the previous Head of School, Professor Jason White, for his leadership and achievements across seven years in the role.